The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels: The Regression Growth Evaluation Statin Study (REGRESS)
Abstract
Background Intensive lowering of serum cholesterol may retard progression of coronary atherosclerosis in selected groups of patients. However, few data are available on the potential benefit of serum cholesterol reduction in the broad range of patients with coronary atherosclerosis and normal to moderately elevated serum cholesterol levels who undergo various forms of treatment. The Regression Growth Evaluation Statin Study (REGRESS) addresses this group of patients. Methods and Results REGRESS is a double-blind, placebo-controlled multicenter study to assess the effects of 2 years of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on progression and regression of coronary atherosclerosis in 885 male patients with a serum cholesterol level between 4 and 8 mmol/L (155 and 310 mg/dL) by quantitative coronary arteriography. Primary end points were (1) change in average mean segment diameter per patient and (2) change in average minimum obstruction diameter per patient. Clinical events were also analyzed. Of the 885 patients, 778 (88%) had an evaluable final angiogram. Mean segment diameter decreased 0.10 mm in the placebo group versus 0.06 mm in the pravastatin group ( P =.019): The mean difference between treatment groups was 0.04 mm, with a 95% CI of 0.01 to 0.07 mm. The median minimum obstruction diameter decreased 0.09 mm in the placebo group versus 0.03 mm in the pravastatin group ( P =.001): The difference of the medians between the treatment groups was 0.06 mm, with a CI of 0.02 to 0.08 mm. At the end of the follow-up period, 89% (CI, 86% to 92%) of the pravastatin patients and 81% (CI, 77% to 85%) of the placebo patients were without new cardiovascular events ( P =.002). Conclusions In symptomatic men with significant coronary atherosclerosis and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Austen, W., Edwards, J., Frye, R., Gensini, G., Gott, V., Griffith, L., McGoon, D., Murphy, M., & Roe, B. (1975) · Circulation · doi:10.1161/01.cir.51.4.5 · Cited by 3,256
Quantitative Determination of Serum Triglycerides by the Use of Enzymes
Bucolo, G., & David, H. (1973) · Clinical Chemistry · doi:10.1093/clinchem/19.5.476 · Cited by 3,188
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.
Schuler, G., Hambrecht, R., Schlierf, G., Niebauer, J., Hauer, K., Neumann, J., Hoberg, E., Drinkmann, A., Bacher, F., & Grunze, M. (1992) · Circulation · doi:10.1161/01.cir.86.1.1 · Cited by 1,340
(1983) · Circulation · doi:10.1161/01.cir.68.5.939 · Cited by 1,199
Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
Vita, J. A., Treasure, C. B., Nabel, E. G., McLenachan, J. M., Fish, R. D., Yeung, A. C., Vekshtein, V. I., Selwyn, A. P., & Ganz, P. (1990) · Circulation · doi:10.1161/01.cir.81.2.491 · Cited by 1,173
Cited by
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish, D. (1998) · JAMA · doi:10.1001/jama.280.23.2001 · Cited by 1,730
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Crisby, M., Nordin-Fredriksson, G., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. (2001) · Circulation · doi:10.1161/01.cir.103.7.926 · Cited by 1,001
(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
O’Rourke, R. A., Brundage, B. H., Froelicher, V. F., Greenland, P., Grundy, S. M., Hachamovitch, R., Pohost, G. M., Shaw, L. J., Weintraub, W. S., Winters, W. L., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00831-7 · Cited by 791
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Tardif, J.-C. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 726
Callister, T. Q., Raggi, P., Cooil, B., Lippolis, N. J., & Russo, D. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392703 · Cited by 682
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 625
Self-citationThe evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
Taylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. N. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 558
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Measurement of Arterial Wall Thickness as a Surrogate Marker for Atherosclerosis
de Groot, E., Hovingh, G. K., Wiegman, A., Duriez, P., Smit, A. J., Fruchart, J.-C., & Kastelein, J. J. P. (2004) · Circulation · doi:10.1161/01.cir.0000131516.65699.ba · Cited by 556
Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H., & Daida, H. (2004) · Circulation · doi:10.1161/01.cir.0000140261.58966.a4 · Cited by 553
von Schacky, C., Angerer, P., Kothny, W., Theisen, K., & Mudra, H. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00003 · Cited by 487
Prevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481
Optimal low-density lipoprotein is 50 to 70 mg/dl
O'Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 477
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 437
Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis
Rosenhek, R., Rader, F., Loho, N., Gabriel, H., Heger, M., Klaar, U., Schemper, M., Binder, T., Maurer, G., & Baumgartner, H. (2004) · Circulation · doi:10.1161/01.cir.0000140723.15274.53 · Cited by 428
Ericsson, C.-G., de Faire, U., Grip, L., Svane, B., Hamsten, A., & Nilsson, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91343-4 · Cited by 426
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Weber, C., Erl, W., Weber, K. S. C., & Weber, P. C. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00324-0 · Cited by 411
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Novaro, G. M., Tiong, I. Y., Pearce, G. L., Lauer, M. S., Sprecher, D. L., & Griffin, B. P. (2001) · Circulation · doi:10.1161/hc4301.098249 · Cited by 392
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y. A., Pasternack, A., & Taskinen, M.-R. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 388
Niebauer, J., Hambrecht, R., Velich, T., Hauer, K., Marburger, C., Kälberer, B., Weiss, C., von Hodenberg, E., Schlierf, G., Schuler, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.8.2534 · Cited by 372
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 367
Statins for Secondary Prevention in Elderly Patients
Afilalo, J., Duque, G., Steele, R., Jukema, J. W., de Craen, A. J. M., & Eisenberg, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.063 · Cited by 350
Self-citationMills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 333
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1451 · Cited by 314
Blauw, G. J., Lagaay, A. M., Smelt, A. H. M., & Westendorp, R. G. J. (1997) · Stroke · doi:10.1161/01.str.28.5.946 · Cited by 311
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 304
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
Rauch, U., Osende, J. I., Fuster, V., Badimon, J. J., Fayad, Z., & Chesebro, J. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00014 · Cited by 297
Clee, S. M., Zwinderman, A. H., Engert, J. C., Zwarts, K. Y., Molhuizen, H. O. F., Roomp, K., Jukema, J. W., van Wijland, M., van Dam, M., Hudson, T. J., et al. (2001) · Circulation · doi:10.1161/01.cir.103.9.1198 · Cited by 291
Self-citationLea, A. P., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199753050-00011 · Cited by 290
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
Byington, R. P., Jukema, J. W., Salonen, J. T., Pitt, B., Bruschke, A. V., Hoen, H., Furberg, C. D., & Mancini, G. B. J. (1995) · Circulation · doi:10.1161/01.cir.92.9.2419 · Cited by 283
Self-citationBergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 282
Self-citationStatin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 278
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
Kroon, A. A., Aengevaeren, W. R. M., van der Werf, T., Uijen, G. J. H., Reiber, J. H. C., Bruschke, A. V. G., & Stalenhoef, A. F. H. (1996) · Circulation · doi:10.1161/01.cir.93.10.1826 · Cited by 275
Self-citationMondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., Pastore, M., Borrello, F., Belcastro, M., Picchi, A., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00010-x · Cited by 266
Effect of statins on atherosclerotic plaque
Almeida, S. O., & Budoff, M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.01.001 · Cited by 263
de Groot, E., van Leuven, S. I., Duivenvoorden, R., Meuwese, M. C., Akdim, F., Bots, M. L., & Kastelein, J. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1163 · Cited by 260
de Groot, E., Jukema, J. W., Montauban van Swijndregt, A. D., Zwinderman, A. H., Ackerstaff, R. G. A., van der Steen, A. F. W., Bom, N., Lie, K. I., & Bruschke, A. V. G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00170-3 · Cited by 258
Self-citationDiagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Schoenhagen, P., Crowe, T., Kapadia, S., & Nissen, S. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.040 · Cited by 147
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Influence of social support on progression of coronary artery disease in women
Wang, H.-X., Mittleman, M. A., & Orth-Gomer, K. (2005) · Social Science & Medicine · doi:10.1016/j.socscimed.2004.05.021 · Cited by 113
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
Crouse, J. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600012-jlr200 · Cited by 66
Hsia, J., Bittner, V., Tripputi, M., & Howard, B. V. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00227-8 · Cited by 43
Janszky, I., Mukamal, K. J., Orth-Gomér, K., Romelsjö, A., Schenck-Gustafsson, K., Svane, B., Kirkeeide, R. L., & Mittleman, M. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.05.012 · Cited by 36
Metadata
- Authors
- Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I.
- Venue
- Circulation
- Published
- 1995-05-15
- Volume
- 91
- Issue
- 10
- Pages
- 2528-2540
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2131275408
- Cited by
- 842
- References
- 28
- FWCI
- 74.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.